Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs......
Surface Oncology to Participate in the 2023 Guggenheim
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation......